Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study

 This article can be used to obtain continuing medical education (CME) category 1 credit at jaacap.org.

 This study was supported by National Institute of Mental Health grants MH-61355 (Dr. Findling) to Case Western Reserve University, MH-61464 (Dr. McClellan) to the University of Washington, MH-62726 (Dr. Frazier) to Harvard Medical School, and MH-61528 (Dr. Sikich) to the University of North Carolina. Drs. Sikich (K23 MH- 01802) and Hlastala (K23 MH70570) were also supported by National Institutes of Health career development awards. The research was conducted in National Institutes of Health-supported Clinical Research Centers at Seattle Children's Hospital, University of Washington (M01-RR-00037), and the University of North Carolina at Chapel Hill (M01-RR00046 and U54RR024383).

 Disclosure: Dr. Findling receives or has received research support, served as a consultant for, and/or served on the speakers' bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson and Johnson, KemPharm, Eli Lilly and Company, Lundbeck, Neuropharm, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and Wyeth. Dr. Frazier receives research funding from or participates in clinical trials with Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Johnson and Johnson, Neuropharm, Otsuka America Pharmaceutical, and Pfizer. Dr. Hamer, in the previous 3 years, received or has receives research support, served as a consultant for and served on a data safety monitoring board/internal displacement monitoring center for Acadia, Allergan, Alpharma, AstraZeneca, Cenerx, Corcept, EnabledMD, Epix, Johnson and Johnson, Novartis, Pepper-Hamilton, Pfizer, SAS Institute, Schwartz, Solvay, Sanofi-Aventis, Takeda, Winston-Strawn (a lawsuit involving Forest, Lundbeck, Sun, Caraco), and Wyeth. He and/or his wife own stock in Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Genentech, Proctor and Gamble, and Sepracor. His wife is retired from Bristol-Myers Squibb. Dr. Liberman serves on the advisory board of Bioline, GlaxoSmithKline, Intracellular Therapies, Eli Lilly and Company, Psychogenics, and Wyeth. He does not receive financial compensation or salary support for his participating as an advisor, except for Intracellular Therapies. He receives grant support from Allon, Forest Labs, Merck, and Pfizer. He holds a patent from Repligen. Dr. Sikick receives research funding or participates in clinical trials with Janssen, Pfizer, Bristol-Myers Squibb, Neuropharm, Curemark, and Seaside Pharmaceuticals. She has received software for a computer intervention in schizophrenia from Posit Science. In the past, Dr. Sikich received research funding from Eli Lilly and Company, Janssen, Pfizer, Otsuka, and AstraZeneca. She has served as a consultant for Sanofi Aventis and ABT Associates. Drs. Johnson, McClellan, Vitiello, McNamara, Hlastala, and Maloney, and Ms. Ritz, Ms. Lingler, Ms. Pierson, Ms. Puglia, Ms. Michael Kaufman, and Ms. Noyes report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(10)00294-7

doi:10.1016/j.jaac.2010.03.013

© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.